Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

被引：52

作者：

Barratt-Due, Andreas ^{[1
,2
,3
]}

Floisand, Yngvar ^{[4
]}

Orrem, Hilde L. ^{[2
,3
]}

Kvam, Ann K. ^{[4
]}

Holme, Pal A. ^{[4
,5
]}

Bergseth, Grethe ^{[6
,7
]}

Tjonnfjore, Geir E. ^{[4
,5
]}

Mollnes, Tom E. ^{[2
,3
,6
,7
,8
]}

机构：

[1] Oslo Univ Hosp, Dept Emergencies & Crit Care, Oslo, Norway

[2] Oslo Univ Hosp, Dept Immunol, PB 4950 Nydalen, N-0424 Oslo, Norway

[3] Univ Oslo, KG Jebsen IRC, N-0316 Oslo, Norway

[4] Oslo Univ Hosp, Dept Haematol, Oslo, Norway

[5] Univ Oslo, Inst Clin Med, Oslo, Norway

[6] Nordland Hosp, Res Lab, Bodo, Norway

[7] Univ Tromso, KG Jebsen TREC, Tromso, Norway

[8] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway

来源：

RHEUMATOLOGY | 2016年 / 55卷 / 07期

关键词：

D O I：

10.1093/rheumatology/kew040

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

[No abstract available]

引用

页码：1337 / 1340

页数：4

共 6 条

[1]

An international serum standard for application in assays to detect human complement activation products [J].

Bergseth, Grethe ;

Ludviksen, Judith K. ;

Kirschfink, Michael ;

Giclas, Patricia C. ;

Nilsson, Bo ;

Mollnes, Tom E. .

MOLECULAR IMMUNOLOGY, 2013, 56 (03) :232-239

[2]

Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome [J].

Cervera, R ;

Font, J ;

Gómez-Puerta, JA ;

Espinosa, G ;

Cucho, M ;

Bucciarelli, S ;

Ramos-Casals, M ;

Ingelmo, M ;

Piette, JC ;

Shoenfeld, Y ;

Asherson, RA .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1205-1209

[3]

Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms [J].

Pierangeli, Silvia S. ;

Chen, Pojen P. ;

Raschi, Elena ;

Scurati, Silvia ;

Grossi, Claudia ;

Borghi, Maria Orietta ;

Palomo, Ivan ;

Harris, E. Nigel ;

Meroni, Pier Luigi .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (03) :236-250

[4]

Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab [J].

Shapira, Iuliana ;

Andrade, Danieli ;

Allen, Steven L. ;

Salmon, Jane E. .

ARTHRITIS AND RHEUMATISM, 2012, 64 (08) :2719-2723

[5]

Mechanisms of aPL-mediated thrombosis: Effects of aPL on endothelium and platelets [J].

Vega-Ostertag M.E. ;

Pierangeli S.S. .

Current Rheumatology Reports, 2007, 9 (3) :190-197

[6]

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo [J].

Volokhina, Elena B. ;

Bergseth, Grethe ;

van de Kar, Nicole C. A. J. ;

van den Heuvel, Lambertus P. ;

Mollnes, Tom Eirik .

BLOOD, 2015, 126 (02) :278-279

← 1 →